- 1 Epidemiological, phylogenetic, and resistance heterogeneity among Acinetobacter baumannii in a major US
- 2 Deep South healthcare center
- 3
- 4 Emma Graffice^a, Derek B. Moates^{bc}, Sixto M. Leal Jr.^{bc}, Megan Amerson-Brown^{bc}, Juan J. Calix^{a#}
- 5
- 6 ^aDepartment of Medicine, Division of Infectious Disease, University of Alabama at Birmingham, Birmingham,
- 7 Alabama, USA
- 8 ^bDepartment of Pathology, Division of Laboratory Science, University of Alabama at Birmingham, Birmingham,
- 9 Alabama, USA
- 10 ^cUniversity of Alabama at Birmingham Hospital Clinical Microbiology, Birmingham, Alabama, USA
- 11
- 12 Running Head: Molecular epidemiological survey of A. baumannii
- 13
- 14 #Address correspondence to Juan J. Calix, juancalix@uabmc.edu.
- 15
- 16 <u>Author contributions:</u>
- 17 J.J.C. and E.G. conceptualized, designed and performed the study. S.M.L., D.B.M., and M.A.B contributed to
- 18 design and completion of the study. E.G. wrote the manuscript first draft. All authors were involved with
- 19 manuscript revisions and approved the final version.

1 Abstract:

Acinetobacter baumannii (Ab) disease in the U.S. is commonly attributed to outbreaks of one or two 2 3 monophyletic carbapenem resistance (CR) Ab lineages that vary by region. However, there is limited 4 knowledge regarding Ab epidemiology and population structure in the U.S. Deep South, and few studies 5 compare contemporary CR and carbapenem-susceptible (Cs) Ab, despite prevalence of the latter. We 6 performed a 12-year time series analysis of Ab cases in a large hospital in Birmingham, AL, and 89 isolates from an ongoing surveillance project started in November 2021 were analyzed by whole genome sequencing 7 8 and antibiotic susceptibility testing (AST). Cumulative CR rate among 2462 cases since 2011 was 19.4%, with 9 increased rates during winter months resulting from seasonal changes in CsAb incidence. Sequenced CRAb 10 belonged to clonal complex (CC) 1, CC108, CC250, CC2, and CC499. Most CRAb CCs were comprised of 11 isolates that clustered apart from U.S. counterparts in phylogenetic analysis, despite being identified in unrelated cases occurring ≥3 months apart. In contrast, 38/47 (81%) CsAb isolates each belonged to a distinct 12 CC. CRAb isolates displayed lineage-distinct AST features, including unique carbapenem resistance genetic 13 14 determinants and presumptive heteroresistance behaviors unique to CC108 and CC499 isolates. This first comprehensive analysis of Ab cases in the U.S. Deep South revealed epidemiological trends consistent with 15 those in other regions and an unusually high degree of phylogenetic diversity among regional CRAb isolates. 16 We also describe emergent U.S. CRAb lineages whose unconventional antimicrobial resistance features must 17 18 be integrated into ongoing diagnostic, treatment, and surveillance efforts.

- 19
- 20
- 21
- 22

23 Introduction

24 The looming global health threat posed by multidrug resistant (MDR) organisms is best exemplified by 25 the ESKAPE pathogens: vancomycin-resistant Enterococcus faecium, methicillin-resistant Staphylococcus aureus, extended-spectrum beta-lactamase (ESBL)-producing Klebsiella pneumoniae, carbapenem-resistant 26 (CR) Acinetobacter baumannii (Ab), multidrug-resistant Pseudomonas aeruginosa, and ESBL Enterobacter 27 species¹. CRAb in particular is considered a top priority for research by the World Health Organization² and 28 U.S. CDC³. This is due to its ability to survive in various environments and its various multidrug resistant 29 (MDR) phenotypes mediated by intrinsic Acinetobacter-derived cephalosporinase (ADC) class C β-lactamases 30 31 and OXA class D β-lactamases, polymorphisms in antibiotic targets, and a variety of other resistance genes --32 including extrinsic OXA and non-OXA carbapenamases -- acquired via mobile genetic elements (e.g., plasmids, transposons, etc.). CRAb disease is conventionally linked to hospital-acquired (HA) respiratory, 33 endovascular, wound, and urinary infections mainly attributable to a subset of MDR global lineages within the 34 otherwise genetically diverse species⁴⁻⁶. 35

Ab strains can be classified according to one of two multilocus sequence type (MLST) schemes⁷, and 36 to avoid confusion, herein we exclusively use the Pasteur MLST scheme⁸. Single locus variant (SLV) 37 sequence types (STs) can be further grouped into monophyletic lineages, or clonal clusters (CC), named 38 according to the prevailing ST. CRAb-associated lineages CC2, CC1 and CC79 comprised 61%, 5% and 3%, 39 respectively, of the ~3500 genomes available on NCBI in early 2019⁹. U.S. clinical Ab populations have 40 41 historically reflected global trends, with CC2 comprising 85% of CRAb isolates in the first nationwide survey performed between 2008-2009¹⁰ and 64% of isolates from CDC sentinel sites between 2013-2017¹¹. 42 In contrast, CC2 comprises <5% of sequenced isolates from Latin American countries⁹, demonstrating that 43 44 regional population structures can vary significantly. Similarly, observations from U.S. single-center studies reveal wide variation over locations and time¹¹⁻¹⁵. For example, most pre-2012 CRAb isolates in a St. Louis, 45 MO healthcare system were CC2 or CC79¹⁰, but local subclones of the unrelated ST406 (CC406) and ST499 46 (CC499), the latter of which was first detected in Chicago in 2010¹⁶, rapidly became the most common CRAb 47 between 2017 and 2019¹³. 48

Awareness of Ab CCs propagating in a region could inform clinical practice, as recent evidence 49 suggests that CRAb lineages each display unique susceptibility patterns to non-carbapenem antibiotics and 50 51 may differ in their epidemiological behavior¹³. Notably, little is known regarding the population structure of Abin the US Deep South. Other than the inclusion of six Florida isolates¹⁰, published surveys have not included 52 isolates from Deep South/Southeast region, where unique climate patterns and socioeconomic factors may 53 selectively favor traits in this environmental microbe absent from pools in other regions. In addition, most 54 recent surveys exclude cases associated with carbapenem-susceptible (Cs) Ab. despite these being a 55 56 common cause of Ab disease and better representing the genetic diversity of the species. Indeed, 59.3% and 22.0% of CRAb isolates sequenced in the St. Louis study (n=59) belonged to ST499 and ST406 outbreaks. 57 58 respectively, but each sequenced CsAb isolate (n=31) belonged to a distinct ST, reflecting a much more sporadic nature of CsAb infections¹³. 59 Here we report early findings from our investigation of *Ab* population dynamics in the U.S. Deep South. 60 We compare the epidemiology of CsAb and CRAb isolates identified over 12 years in a large healthcare 61 62 system in Birmingham, Alabama and characterize the current population structure of clinically-relevant Ab by isolate whole genome sequencing (WGS). We report a link between emergent lineages and atypical 63 antimicrobial resistance phenotypes, and contextualize findings within the greater population structure of Ab 64 65 throughout the U.S. 66

67 Methods

Study location and period. This study was approved by the University of Alabama at Birmingham (UAB)
Institutional Review Board (IRB# 30003572 and 30008212) and was performed in the UAB Healthcare system
from July 1, 2010 to December 31, 2022. UAB is a large integrated inpatient and outpatient healthcare system
serving Birmingham, Alabama, USA and surrounding areas. It employs Cerner electronic medical record
(EMR) systems, which was queried using the Informatics for Integrating Biology and the Bedside (i2b2) tool
hosted by the UAB Center for Clinical and Translation Science (CCTS). UAB Hospital and affiliated clinics use
a central UAB Clinical Microbiology Laboratory (UAB-CML) housed on the main campus.

75

| | 5 |
|----|---|
| 76 | Retrospective study design and definitions. For all cases in which Acinetobacter isolates were identified via |
| 77 | standard of care culture, we retrieved patient demographics, culture tissue source, hospital day of culture (if |
| 78 | applicable), and antibiotic susceptibility testing (AST) interpretation results. The species identity of bacterial |
| 79 | isolates was determined by automated biochemical methods or matrix-assisted laser desorption/ionization and |
| 80 | time-of-flight mass spectroscopy (MALDI-TOF MS) performed in the UAB-CML. Only the first isolate per |
| 81 | patient ("index culture") reported as following was eligible for inclusion: "Acinetobacter baumannii" (n=419), |
| 82 | <i>"Acinetobacter baumannii</i> complex" (n=651), " <i>Acinetobacter baumannii</i> complex/ <i>haemolyticus</i> " (n=5), or |
| 83 | "Acinetobacter baumannii/haemolyticus" (n=1387). Per UAB-CML protocols, all Acinetobacter isolates are |
| 84 | routinely tested for susceptibility via the Beckman Coulter Microscan WalkAway plus AST system. Common |
| 85 | AST within the UAB-CML includes ampicillin-sulbactam (SAM), cefepime (FEP), ceftazidime (CAZ), |
| 86 | ciprofloxacin (CIP), gentamycin (GM), levofloxacin (LVX), trimethoprim-sulfamethoxazole (SXT), tobramycin |
| 87 | (TOB), imipenem (IPM), and meropenem (MEM). AST and susceptibility reporting is performed according to |
| 88 | Clinical and Laboratory Standards Institute (CLSI) guidelines ¹⁷ . |
| 89 | Isolates non-susceptible to either imipenem or meropenem by minimum inhibitory concentration (MIC)- |
| 90 | AST were defined as CR. Cases were classified into 5 anatomical categories according to isolate source: |
| 91 | "respiratory," "skin and soft tissue/musculoskeletal" (SST/MSK), "urinary," "blood" (including isolates obtained |
| 92 | from central lines, endovascular devices, or grafts), or "other." Cases were defined as HA if the index culture |
| 93 | was performed ≥48 hours from time of hospitalization and before discharge. All other isolates were defined as |
| 94 | nHA. To evaluate for seasonal trends among cases identified in 2011-2022, cases were grouped into four |
| 95 | quarters according to the month index culture was obtained: 1 (January-March), 2 (April-June), 3 (July- |
| 96 | September) and 4 (October-December). |
| 97 | |

Prospective isolate banking. Since November 2021, clinical isolates typed as an *Acinetobacter* species by
 MALDI-TOF MS in the UAB-CML were identified via biweekly query of the UAB Cerner EMR system and
 eligible for inclusion. Subclones from original culture plates were transferred to the research laboratory for
 processing. If more than one morphologically distinct colony on culture plate was identified
 as *Acinetobacter*, all colonies were stored. For this staging study, we arbitrarily chose 89 presumptive *Ab*

- isolates identified between November 1, 2021 and November 31, 2022 for sequencing and susceptibility
 testing analysis (Data S1). Herein, study isolates are named by number (e.g., isolate 002 denotes
- 105 UAB_Ab002, etc.).
- 106
- 107 Whole genome sequencing, assembly and comparative genomics. A full description of the well-
- 108 established processing pipelines¹³ used for genome assembly and comparative genomics analyses is provided
- 109 in the Supplementary Text. The earliest isolate with a MLST and/or antimicrobial resistance gene (ARG) profile
- 110 per person was denoted as an index isolate, with subsequent isolates denoted as non-index isolates.
- 111

Kirby-Bauer AST. Study isolates were tested by Kirby-Bauer disk diffusion AST (KB-AST) in our research lab 112 with Mueller-Hinton agar against sulbactam/ampicillin (SAM), cefepime (FEP), ceftazidime (CAZ), meropenem 113 (MEM), imipenem (IPM), trimethroprim/sulfamethoxazole (SXT), ciprofloxacin (CIP), gentamicin (GM) and 114 doxycycline (DOX). Zone of clearance (ZOC) breakpoints were determined and interpreted according to CLSI 115 guidelines¹⁷. In cases where subpopulations of distinct colonies were repeatedly observed growing up to the 116 border of the antibiotic disk but readily distinguishable from the lawn's major border, we subcloned bacteria 117 from colonies at the disk border ("disk subclone") or from the main lawn ("lawn subclone"). Subclones were 118 plated and incubated at 37°C for 16 hours on LB Miller agar without antibiotics and retested by KB-AST the 119 120 next day. Plate images were acquired from a height of 6.3 inches using an iPhone 14 Pro Max with 1x lens and arranged using Adobe Illustrator¹⁸. 121

122

Systematic review of *Ab* isolate population structure in the U.S. Full description of the systematic literature review and comparative genomic meta-analysis is provided in the Supplementary Text. Briefly, a screen on NCBI database was performed on September 18, 2023 and identified 774 genome sequences of *Ab* isolates identified in U.S. populations since 2010 in peer-reviewed reports. We performed *de novo* genome assembly using NCBI SRA files and, when available, extracted epidemiological and microbiological metadata (Data S2). Genomes were binned into CCs according to MLST analysis, and comparative genomic analysis was done within each CC. In the case where a CC of interest was absent among identified genomes (i.e.,

- 130 CC108), we manually screened for genomes on NCBI whose metadata indicated they were isolated in the U.S.
- 131 since 2010.
- 132
- 133Statistical analyses.Univariate analyses were performed with SPSS v29 (IBM, USA) or RStudio software v134 $4.1.2^{19}$. Chi-squared or odd ratio test were performed for comparing categorical variables. Mann-Whitney test135with Bonferroni adjustment for multiple comparisons was performed for continuous variables. Statistical136significance was defined as p value <0.05.</td>
- 137
- Data availability. All raw sequence files and assemblies derived from UAB study strains are available under
 NCBI BioProject PRJNA1005294 (see Data S1).
- 140
- 141 Results
- Retrospective analysis reveals diverse clinical presentations of Ab cases at UAB. We identified 2462 142 cases associated with Ab index cultures at UAB between July 2010 and December 2022, including 478 143 (19.4%) cases with CRAb (Data S3). CsAb but not CRAb case occurrence displayed seasonality, with the 144 selective increase in incidence of Cs cases during third calendar guarters (Figure 1A) resulting in decreased 145 CR rates between May and October (Figure 1B). 41.6% (826/1984) of CsAb cases were HA, compared to 146 147 54.2% (259/478) of CRAb. Though CRAb cases were more likely than CsAb to be HA (54.2% versus 41.6%, OR [CI95%]=1.66 [1.36-2.03]), HA rates fluctuated over time among CRAb. HA rates were 76.9% and 85.7% 148 in late 2010 and early 2011, respectively, but were 27.4% and 45.5% in both halves of 2022 (Data S3). This 149 trend coincided with CRAb cases in later periods being identified earlier during hospitalization (Figure 1C). In 150 151 contrast. CsAb HA rates and median hospital day of isolation were similar in all study periods (Figure 1D). CsAb and CRAb displayed comparable distribution of isolate tissue sources when stratified according to onset 152 (Figure 1E), i.e., respiratory isolates predominated among HA cases, while urinary and SST/MSK isolates 153 predominated among nHA cases in nearly all study periods (Figure 1F). Lastly, CRAb was more likely to be 154 isolated from males (OR [CI95%] = 1.49 [1.21-1.84]), and females comprised less than 40% of CsAb 155 respiratory cases (37.2%) and CRAb respiratory (37.7%), SST/MSK (33.1%) urinary (34.7%), and other 156

- (31.6%) cases (Table S1). There was no difference in average patient age between Cs*Ab* (49.0 years) and
 CR*Ab* (50.3 years, p=0.178) cases. In summary, CR*Ab* and Cs*Ab* were both implicated in various case types
 at UAB, albeit with differential features regarding seasonality, timing of index culture, and patient sex
 distribution.
- 161

2021-2022 UAB Ab isolates demonstrate phylogenetic heterogeneity. To describe the Ab population 162 structure in our cohort, we performed WGS of 89 Ab isolates identified in 2021-2022, including 73 index 163 isolates from all tissue sources, obtained from 68 case patients (Figure 2, Data S1). We identified 31 assigned 164 STs (including ST2139 and ST2140, which were newly assigned in this study) and 11 unassigned STs 165 distributed among 39 CCs (Table S2). Ten cases had >1 Ab isolate included in our WGS analysis, and three 166 patients had two index isolates from unrelated STs (Figure S1). 58.9% (n=43) of index isolates belonged to 167 nine CCs, each containing ≥ 2 index isolates obtained from unrelated cases occurring ≥ 30 days apart (Figure 2, 168 Table S2). Of these, CC108, CC164 and CC427 each contained isolates of two STs. The remaining index 169 isolates (n=30) each belonged to unrelated STs (Data S4). 170

171

172 Antimicrobial susceptibility was linked to lineage dependent and independent genetic elements. We

investigated whether UAB CRAb lineages display distinctive AST profiles, as observed in recent studies¹³. Our 173 174 cohort was comprised of 26 CRAb and 47 CsAb index isolates (Figure 3, Data S1). CC108 and CC499 were exclusively comprised of CRAb, CC150, CC164, CC32 and CC427 were comprised exclusively of CsAb, and 175 CC1, CC2 and CC250 were comprised of both. All remaining isolates were CsAb. ARG analysis revealed all 176 CC499 isolates encode OXA-24, the CC108 isolate 260 encodes OXA-499 (an OXA-143-like carbapenemase), 177 and OXA-23 is encoded in nearly all other CR isolates except isolate 032 (Figure 3). Along with six other 178 CC108 isolates, isolate 032 encodes the FtsI A515V polymorphism, a penicillin-binding protein 3 mutation 179 predicted to decrease carbapenem binding to its active site²⁰. In summary, carbapenem resistance wholly 180 correlated with the presence of attributable genetic elements (Figure 3, Data S4). 181

182 The identity of intrinsic OXA and ADC alleles was largely conserved within a lineage and rarely shared 183 between lineages (Figure 3). Independent of OXA-23 presence, CC1 and CC2 isolates displayed greater FEP

and CAZ resistance than other CsAb, including the CC250 CsAb isolates (Figure S2). Conversely, CC250 and 184 185 CC499 CRAb isolates displayed CAZ susceptibility indistinguishable from CC150 and other CsAb. CC108 isolates displayed the lowest detectable levels of susceptibility across all beta-lactam antibiotics in KB-AST 186 (Figure S2). We observed comparably greater intra-CC variation in the susceptibility to other antibiotic classes. 187 which strongly correlated with the presence of resistance elements repeatedly shared by genomes in multiple 188 lineages (Figure 3 and Figure S2). The only major discrepancy was SXT non-susceptibility in CC499 isolate 189 who lacked the sul1/sul2 gene putatively conferring resistance in all other lineages, which is a trait observed 190 among CC499 isolates in prior studies¹³. 191

192

Atypical resistance phenotypes displayed by CC108 and CC499 isolates. Results from clinical laboratory 193 AST by microbroth dilution (MB-AST) generally matched Kirby-Bauer AST (KB-AST) for most isolates, but two 194 consistent discrepancies were noted (Data S1, S5). First, CC108 isolates displaying the lowest detectable 195 susceptibility to SAM in KB-AST were reported as "intermediate" or "susceptible" according to MB-AST. 196 Second, despite CC499 isolates being reported as "susceptible" to SXT according to MB-AST and lacking 197 conventional resistance gene elements observed in other SXT-resistant isolates, they displayed decreased 198 susceptibility to SXT in KB-AST. Closer review of KB-AST plates found that CC108 isolates against IPM and 199 SAM and CC499 isolates against SXT each displayed subpopulations extending between their main lawn 200 201 margin and the antibiotic disk borders (Figure 4A). Subclones obtained from the lawn or colonies at the antibiotic disk border were incubated overnight without antibiotics, and secondary KB-AST was performed 202 (Figure 4B). Each subclone pair yielded similar results in secondary KB-AST (Figure 4C-E). Similar SXT-203 related phenomenon was observed when testing ST499 isolates identified prior to 2019 in St. Louis (Figure 204 S3)¹³. No other tested isolates displayed similar patterns in KB-AST. 205

206

207 <u>Meta-analysis of contemporary U.S. *Ab* population structures.</u> The equal presence of multiple unrelated 208 CR*Ab* lineages in our cohort was unexpected. To understand how strains in our cohort relate to their lineages 209 in the greater U.S. *Ab* population, we integrated 645 *Ab* genomes from strains isolated in U.S. since 2010 that 210 passed QC (Data S2) and 545 genomes were used for CC-specific comparative analyses (Table S2). UAB

CC2 isolates occupied three branches within two previously described clades^{14,21}, one branch in Clade C 211 212 (isolates 021 and 187) and two in Clade A (isolate 028 and all the others, respectively) (Figure 5). Most CC1, CC499, CC108 and CC250 UAB isolates occupied exclusive branches within their complexes, though two 213 CC250 (isolates 024 and 232) and CC108 isolates (isolates 076 and 260) were on distinct branches. 214 Conversely, UAB CC150 and CC32 genomes were broadly distributed within their respective trees. No CC427 215 or CC164 isolates were identified in the U.S. meta-analysis, and two of the most common U.S. lineages, 216 CC406 (also known as USA-clone-1²²) and CC79 (also known as Clade E¹⁴), were absent from the UAB cohort 217 (Table S2). 218 In ARG analysis of the total U.S. cohort there was within-lineage variability regarding strains harboring 219 220 resistance genetic elements for non-beta-lactam antibiotics (Data S2). In contrast, the allelic identity of intrinsic OXA and ADC genes facilitated the delineation of phylogenetic subclades within clonal complexes, most of 221 which included isolates obtained in different studies and regions (Figure S4). The vast majority of isolates 222 encoding a carbapenemase contained OXA-23. However, OXA-24/72 was the prevalent carbapanemase 223 224 among CC2 isolates in subclades A2, C2 and G (Figure S4B), half of CC79 isolates, two unrelated subclades in CC406, and nearly all non-Mountain region CC499 isolates (Figure S4C). Notably, the FtsI A515V 225 polymorphism was encoded by isolates only in CC2 subclade B2 (Figure S4B) and one CC108 subclade that 226 included isolates lacking any OXA carbapenamase (Figure S4C). CC406 was the only CRAb-associated 227 228 complex in which most isolates had no identifiable carbapenem resistance element. CC150 and CC32 isolates did not encode carbapenamases (Figure S4D). 229

230

231 Discussion

We report a comprehensive analysis of clinical cases associated with *Ab* isolates in a major Deep South U.S. medical center. Aiming to uncover the microbiological landscape of *Ab* propagating in our region, we followed an ecological study design to characterize the presentation of *Ab*-associated cases and the population structure of clinical isolates. Investigation of treatment strategies, outcomes, and transmission networks spurring their presence is the subject of ongoing study in our regional cohort.

Few recent surveys include both CsAb and CRAb in their analyses despite the former being more 237 prevalent among Ab clinical isolates in many regions^{6,23}. CRAb cases were more likely to be HA in our cohort, 238 though the trend of cases being identified earlier in a hospital course did not coincide with a decrease in 239 carbapenem resistance (Data S3), and tissue source distributions of CS and CR isolates were 240 indistinguishable (Figure 1E-F). The observed link between tissue source distribution and case onset as well 241 as the presence of seasonality only among CsAb (Figure 1A-B) is consistent with prior reports^{6,24}. Altogether, 242 these findings support that our cohort is comparable to Ab in other U.S. medical centers. 243 Genomic analysis identified multiple clusters comprised of isolates collected ≥90 days apart, from 244

different tissue sources, and associated with HA and nHA cases (Figure 2), and many of these isolates belong 245 to subclades unique to our region. Attributing Ab clusters to hyperlocalized outbreaks would require a formal 246 clonality analysis beyond the scope of our current study. Regardless, these observations imply the existence of 247 contemporary microbial pools persisting in the region and outside our hospital, as shown in other U.S. 248 regions^{13,14}. While 26 index CRAb belonged to five CCs, 47 CsAb isolates belonged to 37 unrelated lineages. 249 The identification of multiple cases in a single U.S. center caused by single lineages (i.e. CC150 and CC32) 250 has not been reported. However, compared to CRAb isolates, there tended to be greater distance between 251 UAB CsAb isolates within their respective CCs (Figure 5). The relatively decreased relatedness among CsAb 252 isolates is consistent with recent reports¹³, and support that CsAb cases are result of sporadic cross-over 253 254 events from environmental sources.

As a species living in undefined environmental niches, Ab harbors a very diverse genetic pool even 255 compared to other Gram-negative pathogens^{25,26}. Though historically most CRAb disease has been attributed 256 to CC2 isolates, unrelated lineages have recently emerged in the U.S. For example, the first reported 257 incidence of ST499 isolation occurred in 2010¹⁶, but CC499 has now become the second most common 258 lineage among U.S. CRAb isolates and the dominant lineage in some regions^{11,13}. CC108 had been only 259 sporadically observed in prior studies, but our finding support it is capable of establishing a stable presence in 260 a region. Lastly, ST250 was first identified in a 2007 isolate from Puerto Rico²⁷, rarely identified in prior U.S. 261 surveillance, but repeatedly isolated from unrelated cases over the course of our study. As reflected by the 262 relative diversity of CRAb lineages concurrently propagating in our region, climate in the U.S. Deep South may 263

be more permissive to *Ab* phylogenetic diversity than other sites where surveillance has previously been
performed¹¹, and we predict similarly diverse *Ab* population structures would be revealed upon investigation of
other Deep South sites. These findings highlight that we should avoid generalizing historical or even
multicenter study findings to local *Ab* population structures, as the lineages responsible for local cases can
differ drastically from site to site.

The value of surveilling local population structures remains to be determined, as the contribution of Ab 269 phylogeny to pathogenesis and clinical outcomes is unclear. However, consistent with prior findings²⁸, we 270 observed that CRAb lineages can harbor unique antimicrobial resistance features that may influence local 271 medical practices. For example, OXA-23 has historically been the most prevalent carbapenamase among 272 CRAb and, thus, is a target of current and emergent rapid molecular detection tools in clinical labs²⁹. However, 273 we identified U.S. isolates belonging to CC2, CC108, and CC499 that display carbapenem resistance via other 274 resistance determinants (i.e., OXA-24 or the FtsI A515V polymorphism), and the mechanism of carbapenem 275 resistance among CC406 isolates remains to be identified^{13,22} (Figure S4). During the preparation of this 276 manuscript, Sabour, et al. reported that carbapenemase gene content among CRAb differed by region, and 277 these genes did not appear to always confer the same degree of resistance²⁸. Though Sabour et al. did not 278 evaluate whether degree of carbapenem resistance was dependent on lineage, lineage-associated differences 279 were observed previously¹³ and in our study (i.e., OXA-23-associated IPM resistance was greater among CC2 280 281 isolates compared to CC250 isolates, Figure S2). Altogether, this implies that the utility of OXA-23-based testing varies according to which U.S. lineages are circulating in the region. 282

Another concerning finding was the discordance between MB-AST and KB-AST for SAM against 283 CC108 isolates and for SXT against CC499 isolates. The repeated occurrence of subpopulations with different 284 285 susceptibilities and the instability of increased resistance phenotype in subclones together suggest the presence of heteroresistance in these isolates, though further work is required to confirm and characterize this. 286 Why these traits are not readily identifiable via MB-AST, and how the spontaneous occurrence of increased 287 resistance against sulbactam and trimethoprim/sulfamethoxazole influences clinical outcomes or susceptibility 288 289 to new combination agents (i.e., sulbactam-durlobactam), must be evaluated. The dynamic nature of these 290 resistance phenotypes is reminiscent of phase variation, but the mechanisms through which the phenotype is

- achieved require further study. This is especially true for CC499, which appears able to achieve elevated
- 292 resistance to SXT without harboring any of the genetic elements typically associated with SXT resistance in
- 293 other *Ab* lineages (i.e. *sul1* or *sul2*, Figure 3).
- 294 Though consistent with recent reports from other U.S. locations¹¹⁻¹³, our study was performed in a
- single healthcare center and the generalizability of findings to other global *Ab* populations remains to be
- determined. Importantly, our work begins to show how knowledge of isolate lineage could influence clinical
- decision-making and sets a foundation to explore how lineage may influence other aspects of *Ab* disease, such
- as virulence, clinical prognosis, and propensity to be spread among certain patient populations.
- 299
- 300
- - -
- 301
- 302
- 303
- 304
- 305

medRxiv preprint doi: https://doi.org/10.1101/2024.03.22.24304710; this version posted March 25, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.





Figure 1. Divergent epidemiological features of *Ab* cases at UAB, July 2010-December 2022. A) 308 Proportion of annual carbapenem-susceptible A. baumannii (CsAb) and carbapenem-resistant Ab (CRAb) 309 310 cases occurring in each calendar guarter (Q1-Q4) during 2011-2022. **, <0.001. B) Cumulative case total for each month (left v-axis) of CsAb and CRAb (light and dark grav, respectively) and monthly CR rate (dotted line, 311 right y-axis) among cases from 2011-2022. C,D) Semiannual totals (left y-axis) of hospital-acquired (HA) and 312 non-hospital acquired (nHA) CRAb (panel C) and CsAb (panel D) cases. Lines and error bars depict the 313 median and interguartile range (IQR) for hospital day of isolation among cases in each period (right y-axis). 314 315 Panel C key corresponds to both panels. E) Percentage of CRAb and CsAb index isolate from each tissue sources among nHA (left) and HA (right) cases. F) Percentage of index isolates from each source among CR 316 (top row) and Cs (bottom row) cases in each study period, separated by nHA (left column) and HA (right 317

318 column).



319

Figure 2: Diversity of *Ab* isolates at UAB hospitals, 2021-2022. Maximum likelihood phylogenetic tree of UAB *Ab* index isolates according to alignment of 2072 core genes, rooted to the genome of reference strains 19606. Inner label ring denotes CC with >1 index isolate. Filled circles denote CR*Ab* and isolates associated with HA cases. Outer rings represent isolate metadata according to the corresponding keys, as listed in Data S1.



Figure 3: Antibiotic susceptibility and resistance genetic element content of UAB index isolates (top).

328 Tested antibiotics are listed on left and grouped by antibiotic class. Results are presented as "resistant" (red),

329 "intermediate" (pink), or "susceptible" (white) according to CLSI guideline interpretation of Kirby-Bauer results.

- 330 Circles below each AST group denotes presence (fill circle) or absence of associated resistance genetic
- elements listed on right. Intrinsic OXA and ADC alleles are listed by allele number. For clarity, only genetic
- elements present in isolates belonging to multi-isolate CCs (colored columns with labels below) are included.
- Results for all UAB isolates and genetic elements are listed in Data S4.
- 334



Figure 4: KB-AST identifies susceptibility-variable subpopulations associated with CRAb lineage and 336 antibiotic type. A) Representative pictures of the most commonly observed KB-AST results for main CCs in 337 our cohort (left), against different antibiotics (top). Red letters denote samples that were subcloned and 338 incubated overnight on LB agar with no antibiotic followed by secondary KB-AST, as depicted in panel B. C-E) 339 Secondary KB-AST of "lawn" (left) and "disk" (right) subclones. Photos show results from multiple antibiotics 340 (top) and magnification of zones of clearance around antibiotics of interest (bottom). MEM, meropenem; IPM, 341 342 imipenem; CAZ, ceftazidime; FEP, cefepime; SAM, ampicillin-sulbactam; SXT, trimethoprim/sulfamethoxazole; GM, gentamicin. 343

344



Figure 5: Intra-CC phylogeny of U.S. *Ab* populations identified since 2010. Unrooted maximum likelihood phylogenetic trees drawn according to alignment of core genes shared by isolates within each CC. Tree scales located under CC labels represent to 0.001 substitutions per site, with CC1 and CC32 trees presented as half scale compared to others. Leaf markers represent the regions where each isolate was identified, per the inset key. Numbered labels denote study number of carbapenem-resistant (black) or -susceptible (red) isolates in the UAB study.

352

- 353
- 354
- 355



357

Figure S1: Phylogenetic clusters among all *Ab* sequenced isolates in this study. Maximum likelihood tree of all UAB *Ab* isolates, rooted to midpoint. Branches with bootstrap values <90% are labeled. Highlighted and bolded leaves represent isolates obtained from the same patient, matched according to color. Outer boxes are color coded according to key to denote CCs containing >1 index isolate. Carbapenem resistance and index isolates are denoted by filled black and blue circles, respectively.

- 364
- 365

366



367

Figure S2: Kirby-Bauer antimicrobial susceptibility testing (KB-AST) of UAB isolates. Antibiotic 368 susceptibility, according to zone of clearance (mm, y-axis), of CRAb (black dots) and CsAb (white dots) index 369 isolates grouped by CC. Backgrounds highlight ranges for "resistant" (dark) and "intermediate" (light) 370 susceptibility, per CLSI guideline interpretation. Box-plot center lines denote medians; box limits, upper and 371 372 lower quartile values and whiskers, 1.5 times the IQR. Medians were compared to CC150 using Mann-Whitney test with Bonferroni adjustment for multiple comparisons, with asterisks denoting P < 0.05. Abbreviations: CAZ, 373 ceftazidime; CIP, ciprofloxacin; DOX, doxycycline; FEP, cefepime; GM, gentamicin; IPM, imipenem; MEM, 374 375 meropenem; SAM, ampicillin-sulbactam; SXT, trimethoprim-sulfamethaxazole.

Isolate WU_Ab164



378 Figure S3: CC499 isolates from an unrelated cohort also display variable SXT susceptibility. Photos of

379 KB-AST results of CC499 isolate WU_Ab164, against of all tested antibiotics and magnification of zone of

380 clearance around SXT disk (inset). Abbreviations: CAZ, ceftazidime; CIP, ciprofloxacin; DOX, doxycycline;

- 581 FEP, cefepime; GM, gentamicin; IPM, imipenem; MEM, meropenem; SAM, ampicillin-sulbactam; SXT,
- 382 trimethoprim-sulfamethaxazole.





384

Figure S4: CC-wide ARG content among major U.S. lineages associated with CRAb (panels A-C) and

386 CSAb (panel D). Squares denote an isolate's region with color key in panel B. Top rows of matrices in panels

387 A-C show OXA carbapenamases (labels colored according to subclass), followed by non-OXA genetic

388 elements conferring β-lactam resistance in black. The lower lines denote intrinsic OXA (blue) and ADC (black)

lactamase alleles. All genomes contain an ADC allele, but ADC alleles that were detected in only one genome

are omitted for clarity.

Table S1: Distribution of patient sex among UAB *Ab* cases.

| Carbapenem susceptible <i>A. baumannii</i> specimen type | | | | | | | | Carbapenem resistant A. baumannii specimen type | | | | | | | | |
|--|-------|-------|-------------|---------|-------|-------|--|---|-------|-------------|---------|-------|-------|--|--|--|
| | Blood | Other | Respiratory | SST/MSK | Urine | Total | | Blood | Other | Respiratory | SST/MSK | Urine | Total | | | |
| Male | 110 | 39 | 483 | 241 | 231 | 1104 | | 19 | 13 | 130 | 85 | 65 | 311 | | | |
| Female | 91 | 45 | 292 | 228 | 224 | 880 | | 25 | 6 | 71 | 42 | 22 | 166 | | | |
| % female | 45.3% | 53.6% | 37.7% | 48.6% | 49.2% | 44.4% | | 56.8% | 31.6% | 35.3% | 33.1% | 25.3% | 34.7% | | | |
| Sum | 201 | 84 | 775 | 469 | 455 | 1984 | | 44 | 19 | 201 | 127 | 87 | 478 | | | |

393 SST/MSK, skin, soft tissue and musculoskeletal

Table S2: Intra-lineage phenotypic and genotypic breakdowns.

| | | UAB Cohort | | | | | | | | | | | | | U.S. Cohort (NCBI) | | | | | |
|----------------|-------------------|--------------------|-------------------|---------------|---------|---------|-------|-------|------------------|-------|-------------|---------------|------------------------|------------------|---------------------|--------------------------|-------------|---------------|------------------------|-------------------|
| | | Tissue sources (n) | | | | | | | Genomic analysis | | | | | | | | | | | |
| Clonal complex | Days collected | Pasteur MLST | Index isolates | n CRAb (%) | nHA (%) | SST/MSK | Urine | Resp. | Blood | Other | Total genes | Core genes | Core genome SNPs | SNP/core gene | Genomes analyzed | Pasteur MLST | Total genes | Core genes | Core genome SNPs | SNPs/co e gene |
| CC1 | 167 | 734 | 2 | 1 (50) | 1 (50) | 2 | 0 | 0 | 0 | 0 | 2792 | 3497 | 489 | 0.1398 | 4 | 1, 734 | 4210 | 3250 | 19806 | 6.0942 |
| CC2 | 257 | 2 | 7 | 5 (71) | 4 (57) | 2 | 0 | 5 | 0 | 0 | 4570 | 3183 | 1650 | 0.5184 | 398 | 2, 195, 632, 1573 | 31307 | 2411 | 25625 | 10.6284 |
| CC32 | 175 | 32 | 3 | 0 (0) | 0 (0) | 1 | 1 | 0 | 1 | 0 | 3933 | 3275 | 1878 | 0.5734 | 5 | 32 | 4343 | 3190 | 3231 | 1.0129 |
| CC108 | 340 | 108, 2140 | 8 | 8 (100) | 5 (63) | 3 | 2 | 2 | 1 | 0 | 3861 | 3213 | 3339 | 1.0392 | 16 | 108, 2140 | 4550 | 2600 | 15102 | 5.8085 |
| CC150 | 167 | 150 | 5 | 0 (0) | 3 (60) | 2 | 1 | 2 | 0 | 0 | 4152 | 3360 | 14860 | 4.4226 | 7 | 150 | 4458 | 3265 | 14325 | 4.3874 |
| CC164 | 109 | 164, 1131 | 2 | 0 (0) | 1 (50) | 1 | 0 | 0 | 0 | 1 | 3857 | 3231 | 11631 | 3.5998 | NA | NA | NA | NA | NA | NA |
| CC250 | 344 | 250 | 12 | 10 (83) | 5 (42) | 4 | 2 | 5 | 1 | 0 | 4819 | 3334 | 709 | 0.2127 | 15 | 250 | 4645 | 3140 | 1463 | 0.4659 |
| CC427 | 89 | 427, 848 | 2 | 0 (0) | 0 (0) | 0 | 1 | 0 | 1 | 0 | 4261 | 3094 | 15695 | 5.0727 | NA | NA | NA | NA | NA | NA |
| CC499 | 126 | 2139 | 4 | 4 (100) | 1 (25) | 0 | 0 | 2 | 2 | 0 | 3722 | 3677 | 26 | 0.0071 | 53 | 499, 1180, 2139 | 5034 | 3065 | 12489 | 4.0747 |
| CC406 | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | 38 | 406, 1088, 1091, 1562 | 6248 | 2641 | 24797 | 9.3892 |
| CC79 | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | 9 | 79 | 4639 | 3106 | 7655 | 2.4646 |

398 References:

399 1 Rice, L. B. Federal funding for the study of antimicrobial resistance in nosocomial pathogens: no ESKAPE. J Infect Dis 197, 1079-1081 (2008). https://doi.org:10.1086/533452 400 2 Tacconelli, E. et al. Discovery, research, and development of new antibiotics: the WHO priority list of 401 402 antibiotic-resistant bacteria and tuberculosis. Lancet Infect Dis 18, 318-327 (2018). https://doi.org:10.1016/S1473-3099(17)30753-3 403 CDC. Antibiotic Resistance Threats in the United States, 2019. U.S. Department of Health and Human 404 3 Services, CDC (2019). https://doi.org:http://dx.doi.org/10.15620/cdc:82532. 405 Wong, D. et al. Clinical and Pathophysiological Overview of Acinetobacter Infections: a Century of 406 4 Challenges. Clin Microbiol Rev 30, 409-447 (2017). https://doi.org:10.1128/CMR.00058-16 407 Di Venanzio, G. et al. Urinary tract colonization is enhanced by a plasmid that regulates uropathogenic 408 5 409 Acinetobacter baumannii chromosomal genes. Nat Commun 10, 2763 (2019). https://doi.org:10.1038/s41467-019-10706-y 410 6 Calix, J. J., Burnham, J. P. & Feldman, M. F. Comparison of the Clinical Characteristics of Hospital-411 Acquired and Non-Hospital-Acquired Acinetobacter calcoaceticus-baumannii Complex in a Large 412 Midwest US Health Care System. Open Forum Infect Dis 6, ofz423 (2019). 413 https://doi.org:10.1093/ofid/ofz423 414 Gaiarsa, S. et al. Comparative Analysis of the Two Acinetobacter baumannii Multilocus Sequence 7 415 416 Typing (MLST) Schemes. Front Microbiol 10, 930 (2019). https://doi.org:10.3389/fmicb.2019.00930 417 8 Jolley, K. A., Bray, J. E. & Maiden, M. C. J. Open-access bacterial population genomics: BIGSdb software, the PubMLST.org website and their applications. Wellcome Open Res 3, 124 (2018). 418 419 https://doi.org:10.12688/wellcomeopenres.14826.1 420 9 Hamidian, M. & Nigro, S. J. Emergence, molecular mechanisms and global spread of carbapenemresistant Acinetobacter baumannii. Microb Genom 5 (2019). https://doi.org:10.1099/mgen.0.000306 421 422 10 Adams-Haduch, J. M. et al. Molecular epidemiology of carbapenem-nonsusceptible Acinetobacter baumannii in the United States. J Clin Microbiol 49, 3849-3854 (2011). 423 https://doi.org:10.1128/JCM.00619-11 424 425 11 McKay, S. L. et al. Molecular Epidemiology of Carbapenem-Resistant Acinetobacter baumannii in the United States, 2013-2017. Microb Drug Resist 28, 645-653 (2022). 426 https://doi.org:10.1089/mdr.2021.0352 427 428 12 lovleva, A. et al. Carbapenem-Resistant Acinetobacter baumannii in U.S. Hospitals: Diversification of 429 Circulating Lineages and Antimicrobial Resistance. *mBio* **13**, e0275921 (2022). https://doi.org:10.1128/mbio.02759-21 430 13 Calix, J. J. et al. Outpatient clonal propagation propelled rapid regional establishment of an emergent 431 carbapenem-resistant Acinetobacter baumannii lineage ST499Pas. J Infect Dis (2022). 432 https://doi.org:10.1093/infdis/jiac427 433 Adams, M. D. et al. Rapid Replacement of Acinetobacter baumannii Strains Accompanied by Changes 14 434 in Lipooligosaccharide Loci and Resistance Gene Repertoire. mBio 10 (2019). 435 436 https://doi.org:10.1128/mBio.00356-19 Fitzpatrick, M. A., Ozer, E. A. & Hauser, A. R. Utility of Whole-Genome Sequencing in Characterizing 15 437 Acinetobacter Epidemiology and Analyzing Hospital Outbreaks. J Clin Microbiol 54, 593-612 (2016). 438 439 https://doi.org:10.1128/JCM.01818-15 Ozer, E. A., Fitzpatrick, M. A. & Hauser, A. R. Draft Genome Sequence of Acinetobacter baumannii 16 440 441 Strain ABBL099, a Multidrug-Resistant Clinical Outbreak Isolate with a Novel Multilocus Sequence Type. Genome Announc 2 (2014). https://doi.org:10.1128/genomeA.00738-14 442 17 (Clinical and Laboratory Standards Institute, Wayne, PA, 2007). 443 18 Adobe Illustrator (2019). 444 Team, R. C. R: A Language and Environment for Statistical Computing. R Foundation for Statistical 19 445 Computing, Vienna, Austria (2020). 446 20 Hawkey, J. et al. Evolution of carbapenem resistance in Acinetobacter baumannii during a prolonged 447 infection. Microb Genom 4 (2018). https://doi.org:10.1099/mgen.0.000165 448

- Wright, M. S. et al. New insights into dissemination and variation of the health care-associated pathogen Acinetobacter baumannii from genomic analysis. MBio 5, e00963-00913 (2014). https://doi.org:10.1128/mBio.00963-13 Muller, C. et al. A global view on carbapenem-resistant Acinetobacter baumannii. mBio 14, e0226023 (2023). https://doi.org:10.1128/mbio.02260-23 Gales, A. C. et al. Antimicrobial Susceptibility of Acinetobacter calcoaceticus-Acinetobacter baumannii Complex and Stenotrophomonas maltophilia Clinical Isolates: Results From the SENTRY Antimicrobial Surveillance Program (1997-2016). Open Forum Infect Dis 6, S34-S46 (2019). https://doi.org:10.1093/ofid/ofy293 Burnham, J. P., Feldman, M. F. & Calix, J. J. Seasonal Changes in the Prevalence of Antibiotic-Susceptible Acinetobacter calcoaceticus-baumannii Complex Isolates Result in Increased Multidrug Resistance Rates During Winter Months. Open Forum Infect Dis 6, ofz245 (2019). https://doi.org:10.1093/ofid/ofz245 Chan, A. P. et al. A novel method of consensus pan-chromosome assembly and large-scale comparative analysis reveal the highly flexible pan-genome of Acinetobacter baumannii. Genome Biol 16, 143 (2015). https://doi.org:10.1186/s13059-015-0701-6 Park, S. C., Lee, K., Kim, Y. O., Won, S. & Chun, J. Large-Scale Genomics Reveals the Genetic Characteristics of Seven Species and Importance of Phylogenetic Distance for Estimating Pan-Genome Size. Front Microbiol 10, 834 (2019). https://doi.org:10.3389/fmicb.2019.00834 Martinez, T., Ropelewski, A. J., Gonzalez-Mendez, R., Vazquez, G. J. & Robledo, I. E. Draft Genome Sequence of Klebsiella pneumoniae Carbapenemase-Producing Acinetobacter baumannii Strain M3AC9-7, Isolated from Puerto Rico. Genome Announc 3 (2015). https://doi.org:10.1128/genomeA.00274-15 Sabour, S. et al. Descriptive analysis of targeted carbapenemase genes and antibiotic susceptibility profiles among carbapenem-resistant <i>Acinetobacter baumannii</i> tested in the Antimicrobial Resistance Laboratory Network—United States, 2017–2020. Microbiology Spectrum 12, e02828-02823 (2024). https://doi.org:doi:10.1128/spectrum.02828-23 Vasilakopoulou, A. et al. A multicentre evaluation of the NG-test DetecTool OXA-23 for the rapid detection of OXA-23 carbapenemase directly from blood cultures. JAC Antimicrob Resist 6, dlae029 (2024), https://doi.org:10.1093/jacamr/dlae029

-









Ы В

SXT

SAM

БПР

CAZ

ΡM

MEM















Isolate WU_Ab164

